{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:57:04Z","timestamp":1784937424352,"version":"3.55.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Bisphosphonate drugs can be used to improve the outcomes of women with breast cancer. Whilst many meta-analyses have quantified their potential benefits for patients, attempts at comprehensive quantification of potential adverse effects have been limited. We undertook a meta-analysis with novel methodology to identify and quantify these adverse effects.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We systematically reviewed randomised controlled trials in breast cancer where at least one of the treatments was a bisphosphonate (zoledronic acid, ibandronate, pamidronate, alendronate or clodronate). Neoadjuvant, adjuvant and metastatic settings were examined. Primary outcomes were adverse events of any type or severity (excluding death). We carried out pairwise and network meta-analyses to estimate the size of any adverse effects potentially related to bisphosphonates. In order to ascertain whether adverse effects differed by individual factors such as age, or interacted with other common adjuvant breast cancer treatments, we examined individual-level patient data for one large trial, AZURE.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Findings<\/jats:title>\n<jats:p>We identified 56 trials that reported adverse data, which included a total of 29,248 patients (18,301 receiving bisphosphonate drugs versus 10,947 not). 24 out of the 103 different adverse outcomes analysed showed a statistically and practically significant increase in patients receiving a bisphosphonate drug compared with those not (2 additional outcomes that appeared statistically significant came only from small studies with low event counts and no clinical suspicion so are likely artifacts). Most of these 24 are already clinically recognised: \u2018flu-like symptoms, fever, headache and chills; increased bone pain, arthralgia, myalgia, back pain; cardiac events, thromboembolic events; hypocalcaemia and osteonecrosis of the jaw; as well as possibly stiffness and nausea. Oral clodronate appeared to increase the risk of vomiting and diarrhoea (which may also be increased by other bisphosphonates), and there may be some hepatotoxicity. Four additional potential adverse effects emerged for bisphosphonate drugs in this analysis which have not classically be recognised: fatigue, neurosensory problems, hypertonia\/muscle spasms and possibly dysgeusia. Several symptoms previously reported as potential side effects in the literature were not significantly increased in this analysis: constipation, insomnia, respiratory problems, oedema or thirst\/dry mouth. Individual patient-level data and subgroup analysis revealed little variation in side effects between women of different ages or menopausal status, those with metastatic versus non-metastatic cancer, or between women receiving different concurrent breast cancer therapies.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This meta-analysis has produced estimates for the absolute frequencies of a range of side effects significantly associated with bisphosphonate drugs when used by breast cancer patients. These results show good agreement with previous literature on the subject but are the first systematic quantification of side effects and their severities. However, the analysis is limited by the availability and quality of data on adverse events, and the potential for bias introduced by a lack of standards for reporting of such events. We therefore present a table of adverse effects for bisphosphonates, identified and quantified to the best of our ability from a large number of trials, which we hope can be used to improve the communication of the potential harms of these drugs to patients and their healthcare providers.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0246441","type":"journal-article","created":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T18:23:10Z","timestamp":1612722190000},"page":"e0246441","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["The adverse effects of bisphosphonates in breast cancer: A systematic review and network meta-analysis"],"prefix":"10.1371","volume":"16","author":[{"given":"Christopher","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4115-161X","authenticated-orcid":true,"given":"Alexandra L. J.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z\u015bofia","family":"Szlamka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Spiegelhalter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"pone.0246441.ref001","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1369-6513.2001.00140.x","article-title":"A measure of informed choice","volume":"4","author":"TM Marteau","year":"2001","journal-title":"Heal Expect"},{"key":"pone.0246441.ref002","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.3747\/co.22.2322","article-title":"Systemic targeted therapy for HER2-positive early female breast cancer: A systematic review of the evidence for the 2014 cancer care Ontario systemic therapy guideline","volume":"22","author":"M Mates","year":"2015","journal-title":"Curr Oncol"},{"key":"pone.0246441.ref003","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.3747\/co.22.2326","article-title":"Adjuvant endocrine therapy for early breast cancer: A systematic review of the evidence for the 2014 cancer care Ontario systemic therapy guideline.","volume":"22","author":"OC Freedman","year":"2015","journal-title":"Curr Oncol"},{"key":"pone.0246441.ref004","article-title":"Trastuzumab containing regimens for metastatic breast cancer","author":"L Moja","year":"2006","journal-title":"Cochrane Database Syst Rev."},{"key":"pone.0246441.ref005","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100 000 women in 123 randomised trials","volume":"379","author":"K Albain","year":"2012","journal-title":"Lancet"},{"key":"pone.0246441.ref006","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials","volume":"386","author":"R Bradley","year":"2015","journal-title":"Lancet"},{"key":"pone.0246441.ref007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/bcr414","article-title":"Development of bisphosphonates","volume":"4","author":"H Fleisch","year":"2002","journal-title":"Breast Cancer Res"},{"key":"pone.0246441.ref008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bone.2011.02.003","article-title":"Bisphosphonates in oncology","volume":"49","author":"RE Coleman","year":"2011","journal-title":"Bone"},{"key":"pone.0246441.ref009","article-title":"Bisphosphonates and other bone agents for breast cancer (Review).","author":"B O\u2019Carrigan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0246441.ref010","article-title":"Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Systematic Review 1","author":"S Dhesy-Thind","year":"2017","journal-title":"Ontario"},{"key":"pone.0246441.ref011","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2015","journal-title":"Lancet"},{"key":"pone.0246441.ref012","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: Mechanisms of Action","volume":"19","author":"H Fleisch","year":"1998","journal-title":"Endocr Rev"},{"key":"pone.0246441.ref013","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2217\/cer.12.72","article-title":"Adverse events across generations of bone-modifying agents in patients with solid tumor cancers reported in Phase III randomized trials","volume":"2","author":"M Poon","year":"2013","journal-title":"J Comp Eff Res"},{"key":"pone.0246441.ref014","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1159\/000368844","article-title":"Breast Care Side Effects of Bone-Targeted Therapies in Advanced Breast Cancer.","volume":"9","author":"C Domschke","year":"2014","journal-title":"Breast Care"},{"key":"pone.0246441.ref015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2165\/00002018-199614030-00003","article-title":"Adverse Effects of Bisphosphonates: A Comparative Review","volume":"14","author":"S Adami","year":"1996","journal-title":"Drug Saf"},{"key":"pone.0246441.ref016","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.","volume":"61","author":"R Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"pone.0246441.ref017","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","article-title":"Characterization of and risk factors for the acute-phase response after zoledronic acid","volume":"95","author":"IR Reid","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0246441.ref018","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10549-012-1973-0","article-title":"Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results","volume":"133","author":"S Takahashi","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0246441.ref019","first-page":"384","article-title":"Stimulation of \u03b3\u03b4 T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma","volume":"96","author":"V Kunzmann","year":"2000","journal-title":"Hematology"},{"key":"pone.0246441.ref020","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1200\/JCO.2010.28.7524","article-title":"Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer","volume":"28","author":"GS Wilkinson","year":"2010","journal-title":"J Clin Oncol"},{"key":"pone.0246441.ref021","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis","volume":"356","author":"DM Black","year":"2007","journal-title":"N Engl J Med"},{"key":"pone.0246441.ref022","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"T Tanvetyanon","year":"2006","journal-title":"Ann Oncol"},{"key":"pone.0246441.ref023","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity.","volume":"74","author":"MA Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"pone.0246441.ref024","unstructured":"Joint Formulary Committee British National Formulary (online). In: London BMJ Gr. Pharm. Press. http:\/\/www.medicinescomplete.com. Accessed 31 May 2020."},{"key":"pone.0246441.ref025","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-011-1429-y","article-title":"Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01\u201304) for women with stage II\/III breast cancer.","volume":"127","author":"R Coleman","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0246441.ref026","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"M Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"pone.0246441.ref027","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/02841860801964988","article-title":"Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer","volume":"47","author":"B Kristensen","year":"2008","journal-title":"Acta Oncol (Madr)"},{"key":"pone.0246441.ref028","first-page":"26","article-title":"meta: An R Package for Meta-Analysis.","volume":"7","author":"G Schwarzer","year":"2007","journal-title":"R News"},{"key":"pone.0246441.ref029","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/rssa.12275","article-title":"A re-evaluation of fixed effect(s) meta-analysis.","volume":"181","author":"K Rice","year":"2018","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"pone.0246441.ref030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor","volume":"36","author":"W Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"pone.0246441.ref031","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"DJ Spiegelhalter","year":"2002","journal-title":"J R Stat Soc"},{"key":"pone.0246441.ref032","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"PE Goss","year":"2011","journal-title":"N Engl J Med"},{"key":"pone.0246441.ref033","first-page":"316","article-title":"Corrplot: Visualization of a Correlation Matrix","volume":"56","author":"T Wei","year":"2017","journal-title":"Statistician"},{"key":"pone.0246441.ref034","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.ijrobp.2007.04.054","article-title":"Improving the Capture of Adverse Event Data in Clinical Trials: The Role of the International Atomic Energy Agency","volume":"69","author":"SE Davidson","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"pone.0246441.ref035","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.ejca.2006.03.004","article-title":"Intentional and non-intentional non-adherence to medication amongst breast cancer patients","volume":"42","author":"L Atkins","year":"2006","journal-title":"Eur J Cancer"},{"key":"pone.0246441.ref036","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10549-007-9548-1","article-title":"Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy","volume":"107","author":"D Cella","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0246441.ref037","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.breast.2005.08.012","article-title":"Acceptance of adjuvant therapy and quality of life issues","volume":"14","author":"L Fallowfield","year":"2005","journal-title":"Breast"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T18:23:49Z","timestamp":1612722229000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246441"}},"subtitle":[],"editor":[{"given":"Spyridon N.","family":"Papageorgiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0246441","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]}}}